4DX Share Price Performance
AU$0
-0.55 (-100.00%)
Price AU$0
Fair ValueAU$3.40
Share Pricen/a
4DMedical Limited Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 59 Fair Values set on narratives written by author
4DX Community Narratives
AN
Fair Value AU$3.4 14.1% overvalued intrinsic discount
Recent Regulatory Wins And Reimbursement Approvals Will Drive Broader Market Access
0users have liked this narrative
0users have commented on this narrative
38users have followed this narrative
ET
Fair Value AU$11.11 65.1% undervalued intrinsic discount
4DMedical will begin to soar with rapid expansion and growth over the next year, (And scale majorly over the next 3 years)
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
4DMedical will begin to soar with rapid expansion and growth over the next year, (And scale majorly over the next 3 years)
4DMedical is the first non-invasive, contrast free imaging technology for the lung scanning. New CT:VQ lung scanner is the first technology of its kind and is rapidly being adopted by clinics and big name KOL's in America.Read more
19
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
ET
AU$11.11
65.1% undervalued intrinsic discount
ethanwong's Fair Value
Revenue
205.61% p.a.
Profit Margin
91%
Future PE
48x
Price in 2029
AU$14.79
Recent Regulatory Wins And Reimbursement Approvals Will Drive Broader Market Access
Key Takeaways Strategic acquisitions, partnerships, and regulatory approvals are poised to enhance market presence, revenue, and net margins through expanded distribution and high-margin services. Geographic expansion and new technology development aim to increase market penetration, scan volumes, and capture significant market share, improving overall financial performance.Read more
1.1k
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
38users have followed this narrative
AN
AU$3.4
14.1% overvalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
116.11% p.a.
Profit Margin
18.97%
Future PE
188.31x
Price in 2029
AU$4.28
Trending Discussion
Recently Updated Narratives
ET
4DMedical will begin to soar with rapid expansion and growth over the next year, (And scale majorly over the next 3 years)
Fair Value: AU$11.11 65.1% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
4DX: Equity Raise And New CFO Will Likely Fail To Support Multiple
Fair Value: AU$3.4 14.1% overvalued intrinsic discount
38 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
4DMedical Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.053
- 92.07%
- -513.72%
- 0%
About 4DX
- Founded
- 2012
- Employees
- 124
- CEO
- WebsiteView website
4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in the medical research technology and development of a non-invasive respiratory imaging solution using four-dimensional imaging. It offers CT:VQ, non contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function imaging software; IQ-UIP, a state-of-the-art software; LDAf, Patented Parametric Response Mapping (PRM) technology; LDAi, an automated detection of potential emphysema software; LTA provides visualization and quantification of the lung textures; PHA Analysis, a cutting-edge, fully-automated imaging solution; XV LVAS, a lung airflow imaging software; and XV Scanner, a lung function scanner. The company was incorporated in 2012 and is based in Carlton, Australia.
